Agilent agrees to buy digital pathology platform Proscia for $240m upfront

Agilent Technologies has agreed to buy Proscia, a digital pathology software company, for $240 million in cash upfront plus up to $30 million in milestone payments tied to future performance¹². Agilent expects to complete the deal early in its 2027 fiscal year, which begins on 1 November¹.

What Agilent is buying

The asset is Concentriq, Proscia's software platform, which acts as a central operating layer for digital pathology and links slide scanners, laboratory information systems and other steps in the pathology workflow¹². Customers use it to manage images, data and workflows². Fierce Biotech notes that Concentriq is built for broad use across clinical diagnosis and life sciences research and supports third-party AI applications, where many rival pathology software firms concentrate on diagnosing specific diseases such as cancer².

Proscia's business is focused on the US and Europe. It serves more than 4,000 laboratories, hospitals and clinics and 16 of the top 20 pharmaceutical companies, and its revenue over the past 12 months exceeded $18 million¹. Evercore ISI analysts put its growth rate above 20%¹.

Agilent chief executive Padraig McDonnell said the deal creates a platform "for scientific intelligence in tissue-based precision medicine, connecting data generation with AI-based interpretation in a workflow that supports biomarker research through routine clinical use"¹. Agilent described Proscia as a "high-growth, high-margin software business"¹.

What it means for the market

The deal puts a second large diagnostics group in control of an AI-ready pathology software layer within months. Roche agreed in May 2026 to buy PathAI for up to $1.05 billion, and Evercore analysts said Agilent "got the rights to play in this market at a lower price point"¹. For investors in pathology AI, the two deals give a sense of what strategic buyers are paying for software that sits between scanners, laboratory systems and algorithms.

The commercial logic rests on distribution. Evercore expects Agilent to begin selling Proscia's software to its existing Dako customers as soon as the deal closes, and sees room for Proscia's growth to speed up because of the channel synergies the deal creates¹. The analysts also expect gross margins to be healthy because Proscia is a software business, while calling the takeover "a small deal in the overall scheme of things"¹.

For AI pathology developers, Concentriq's support for third-party applications matters². What changes for algorithm vendors that plug into it under an instrument and reagent supplier is not yet known: the sources do not say how Agilent will treat third-party AI after closing.

For hospital laboratories and pharma customers already on Concentriq, the platform moves from an independent vendor to a large supplier with an existing pathology portfolio. McDonnell said the deal will help laboratories and biopharma customers manage pathology data and draw insights from it². The sources give no detail on pricing, product roadmap or integration plans.

The two companies already knew each other. They signed a distribution agreement for a combined digital diagnostic pathology system, which Fierce Biotech dates to September 2022 and MedTech Dive to 2023¹². Agilent also signed a co-promotion deal with Visiopharm, another digital pathology company, in 2020¹.

Caveats

The financial picture comes mainly from Agilent's statements and one analyst note; Proscia's growth rate and margin outlook are Evercore's estimates rather than reported figures¹. The deal has not closed, and the sources do not mention regulatory or other conditions. Agilent expects completion early in its fiscal 2027, which starts on 1 November 2026¹.